Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.

Meredith M Regan Opeyemi A JagedeCharlene M MantiaThomas PowlesLillian WernerRobert J MotzerNizar M TannirChung-Han Lee Yoshihiko Tomita Martin H VossElizabeth R PlimackToni K ChoueiriBrian I RiniHans J HammersBernard EscudierLaurence AlbigesStephen HuoViviana Del TejoBrian StwalleyMichael B AtkinsDavid F McDermott

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Patients initiating first-line nivolumab plus ipilimumab for aRCC spent more survival time treatment-free without toxicity versus those on sunitinib, regardless of risk group.

Keyphrases

free survival
renal cell carcinoma
end stage renal disease
chronic kidney disease
ejection fraction
clinical trial
stem cells
oxidative stress
replacement therapy
patient reported outcomes
smoking cessation
patient reported
double blind